Etoricoxib (Arcoxia) is a COX-2 careful inhibitor from Merck & Co. Currently it is accustomed in added than 80 countries common but not in the US, area the Food and Drug Administration (FDA) has appropriate added assurance and ability abstracts for etoricoxib afore it will affair approval.
Some analytic trials and meta-analysis showed that analysis with some coxibs (in accurate rofecoxib) led to added accident of adverse cardiovascular contest compared to placebo. Because of these results, some drugs were aloof from the bazaar (rofecoxib, in September 2004 and valdecoxib in April 2005). In addition, the United States Food and Drug Administration and the European Medicines Agency started afterlight processes of the absolute chic of both NSAIDs and COX-2 inhibitors.
In April 2007, the FDA issued Merck a “non-approvable letter” for etoricoxib. The letter said Merck needs to accommodate added analysis after-effects assuming that the drug’s allowances outweigh its risks afore it has addition adventitious of accepting approved.